/ /

  • linkedin
  • Increase Font
  • Sharebar

    Positive results reported for anti-interleukin-6 agent for uveitis

    By Cheryl Guttman Krader

    Las Vegas—Intravenous administration of the anti-interleukin-6 (IL-6) agent tocilizumab (Actemra, Genentech) is well-tolerated in patients with non-infectious uveitis involving the posterior segment and showing promising efficacy, according to interim outcomes reported by Quan Dong Nguyen, MD.

    Speaking at the 2015 meeting of the American Academy of Ophthalmology, a total of 37 patients were entered at 5 sites across the United States into the investigator-sponsored study known as STOP-UVEITIS.

    Patients were randomly assigned to receive tocilizumab 4 or 8 mg/kg. Treatment was initiated with 6 mandatory infusions at 1-month intervals. The primary endpoint was assessed at 6 months, and then tocilizumab administration was changed to an “as needed” basis.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results